恩威医药
(301331)
| 流通市值：27.68亿 | | | 总市值：27.75亿 |
| 流通股本：1.03亿 | | | 总股本：1.03亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 175,328,944.36 | 900,771,087.12 | 636,853,560 | 449,221,452.75 |
| 营业收入 | 175,328,944.36 | 900,771,087.12 | 636,853,560 | 449,221,452.75 |
| 利息收入 | - | 0 | - | - |
| 已赚保费 | - | 0 | - | - |
| 手续费及佣金收入 | - | 0 | - | - |
| 二、营业总成本 | 163,762,300.69 | 842,272,742.13 | 603,849,773.06 | 408,252,811.68 |
| 营业成本 | 77,688,967 | 454,778,491.76 | 329,741,094.37 | 228,665,720.71 |
| 利息支出 | - | 0 | - | - |
| 手续费及佣金支出 | - | 0 | - | - |
| 退保金 | - | 0 | - | - |
| 赔付支出净额 | - | 0 | - | - |
| 提取保险合同准备金净额 | - | 0 | - | - |
| 保单红利支出 | - | 0 | - | - |
| 分保费用 | - | 0 | - | - |
| 税金及附加 | 1,891,907.28 | 11,272,037.86 | 7,706,635.08 | 5,351,510.43 |
| 销售费用 | 65,998,687.9 | 301,142,873.72 | 210,066,218.18 | 136,750,988.16 |
| 管理费用 | 16,727,582.78 | 69,943,838.4 | 51,950,007.37 | 34,640,236.72 |
| 研发费用 | 1,114,464.19 | 5,522,560.06 | 4,302,882.29 | 2,538,865.32 |
| 财务费用 | 340,691.54 | -387,059.67 | 82,935.77 | 305,490.34 |
| 其中:利息费用 | 578,125 | 2,561,203.19 | 2,252,232.68 | 1,645,288.24 |
| 其中:利息收入 | 300,085.69 | 3,143,438.4 | 2,319,824.36 | 1,448,947.99 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | - | -4,315,689.39 | - | - |
| 加:投资收益 | 1,391,909.91 | 5,200,000.98 | 4,140,865.67 | 2,818,800.74 |
| 净敞口套期收益 | - | 0 | - | - |
| 汇兑收益 | - | 0 | - | - |
| 资产处置收益 | - | -138,008.49 | -263,274.66 | -263,274.66 |
| 资产减值损失(新) | -371,726.67 | 1,978,345.29 | 3,109,451.04 | 1,948,506.26 |
| 信用减值损失(新) | 565,933.87 | -1,884,835.73 | 1,043,729.5 | -1,278,804.58 |
| 其他收益 | 937,390.08 | 3,020,886.05 | 2,322,109.27 | 1,707,535.87 |
| 四、营业利润 | 14,090,150.86 | 62,359,043.7 | 43,356,667.76 | 45,901,404.7 |
| 加:营业外收入 | 1.02 | 2,129,004.62 | 53,413.64 | 41,133.13 |
| 减:营业外支出 | 207,248.45 | 324,292.27 | 222,519.93 | 213,098.44 |
| 五、利润总额 | 13,882,903.43 | 64,163,756.05 | 43,187,561.47 | 45,729,439.39 |
| 减:所得税费用 | 1,378,171.11 | 12,218,819.4 | 6,602,899.8 | 7,385,258.14 |
| 六、净利润 | 12,504,732.32 | 51,944,936.65 | 36,584,661.67 | 38,344,181.25 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 12,504,732.32 | 51,944,936.65 | 36,584,661.67 | 38,344,181.25 |
| 终止经营净利润 | - | 0 | - | - |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 12,504,732.32 | 51,944,936.65 | 36,584,661.67 | 38,344,181.25 |
| 少数股东损益 | - | 0 | - | - |
| 扣除非经常损益后的净利润 | 10,695,869.85 | 46,522,944.73 | 31,871,915.37 | 35,275,716.98 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.12 | 0.5 | 0.37 | 0.38 |
| (二)稀释每股收益 | 0.12 | 0.5 | 0.37 | 0.38 |
| 八、其他综合收益 | - | 0 | - | - |
| 归属于母公司股东的其他综合收益 | - | 0 | - | - |
| 九、综合收益总额 | 12,504,732.32 | 51,944,936.65 | 36,584,661.67 | 38,344,181.25 |
| 归属于母公司股东的综合收益总额 | 12,504,732.32 | 51,944,936.65 | 36,584,661.67 | 38,344,181.25 |
| 归属于少数股东的综合收益总额 | - | 0 | - | - |
| 公告日期 | 2026-04-27 | 2026-04-27 | 2025-10-30 | 2025-08-26 |
| 审计意见(境内) | | 标准无保留意见 | | |